£68.15

This is the most expensive it has ever been. Walk away.

£68 today · previous high £68 · all-time low £67

National Academies Press A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 71 days · 71 data points (no recent data)

Historical
Generating forecast…
£68.15 £66.70 £67.01 £67.33 £67.65 £67.97 £68.28 25 July 2026 11 August 2026 29 August 2026 15 September 2026 03 October 2026
View at Amazon ↗

Price data last checked 20 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 71 days • 2 price levels

Days at Price
Current Price
34 days 37 days · current 0 9 19 28 37 £67 £68 Days at Price

Price Analysis

Most common price: £68 (37 days, 52.1%)

Price range: £67 - £68

Price levels: 2 different prices over 71 days

Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of worlda (TM)s hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.

Product Specifications
Brand
National Academies Press
Format
paperback
ASIN
0309457297
Category
Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Infectious & Contagious Diseases
Domain
Amazon UK
Release Date
30 June 2017
Listed Since
01 April 2017

Barcode

No barcode data available

Similar Products You Might Like

Hepatitis B and C: Management and Treatment
98% match

Hepatitis B and C: Management and Treatment

CRC Press

£145.99 24 Sep 2026
Chronic Viral Hepatitis: Management and Control
98% match

Chronic Viral Hepatitis: Management and Control

Foster Academics

£75.27 19 Sep 2026
Viral Hepatitis
98% match

Viral Hepatitis

Wiley

£93.48 19 Sep 2026
Hepatitis C Virus II: Infection and Disease: 2
97% match

Hepatitis C Virus II: Infection and Disease: 2

Springer

£128.12 18 Sep 2026
The Molecular Medicine of Viral Hepatitis (Molecular Medical Science Series)
97% match

The Molecular Medicine of Viral Hepatitis (Molecular Medical Science Series)

Wiley

Price unavailable
Viral Hepatitis Molecular Biology Diagnosis and Control (Volume 10) (Perspectives in Medical Virology, Volume 10)
97% match

Viral Hepatitis Molecular Biology Diagnosis and Control (Volume 10) (Perspectives in Medical Virology, Volume 10)

Elsevier

£26.87 02 Oct 2026
Hepatitis C Virus: From Laboratory to Clinic
97% match

Hepatitis C Virus: From Laboratory to Clinic

Cambridge University Press

£61.53 22 Sep 2026
Hepatitis B Research Advances
97% match

Hepatitis B Research Advances

£38.92 24 Sep 2026
Hepatitis C Infection as a Systemic Disease:Extra-HepaticManifestation of Hepatitis C, An Issue of Clinics in Liver Disease (Volume 21-3) (The Clinics: Internal Medicine, Volume 21-3)
97% match

Hepatitis C Infection as a Systemic Disease:Extra-HepaticManifestation of Hepatitis C, An Issue of Clinics in Liver Disease (Volume 21-3) (The Clinics: Internal Medicine, Volume 21-3)

Elsevier

£69.54 17 Sep 2026
Hepatitis B Virus in Human Diseases (Molecular and Translational Medicine)
97% match

Hepatitis B Virus in Human Diseases (Molecular and Translational Medicine)

Humana

£61.84 23 Sep 2026
The Hepatitis C Viruses: 242 (Current Topics in Microbiology and Immunology, 242)
97% match

The Hepatitis C Viruses: 242 (Current Topics in Microbiology and Immunology, 242)

Springer

£76.07 22 Sep 2026
Hepatitis B: The Virus, the Disease, and the Vaccine
97% match

Hepatitis B: The Virus, the Disease, and the Vaccine

Springer

£109.07 24 Sep 2026
Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition
97% match

Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition

Elsevier

£97.79 25 Sep 2026
Comprehensive Guide to Hepatitis Advances - Medical Reference
97% match

Comprehensive Guide to Hepatitis Advances - Medical Reference

Elsevier

£119.99 03 Oct 2026
Overcoming Barriers to Eliminate Hepatitis C, An Issue of Infectious Disease Clinics of North America (Volume 32-2) (The Clinics: Internal Medicine, Volume 32-2)
97% match

Overcoming Barriers to Eliminate Hepatitis C, An Issue of Infectious Disease Clinics of North America (Volume 32-2) (The Clinics: Internal Medicine, Volume 32-2)

Elsevier

£80.96 24 Sep 2026
Hepatitis: An Issue of Clinics in Liver Disease
97% match

Hepatitis: An Issue of Clinics in Liver Disease

Callisto Reference

£69.64 19 Sep 2026
Hepatitis C: Methods and Protocols: 510 (Methods in Molecular Biology, 510)
97% match

Hepatitis C: Methods and Protocols: 510 (Methods in Molecular Biology, 510)

Humana

£102.47 02 Oct 2026